The Xen implant is an ab interno device that has been shown to be effective in reducing intraocular pressure in several types of glaucoma, although the evidence in pseudoexfoliative glaucoma is limited. The present retrospective observational study aims to increase knowledge about the long-term effectiveness and safety of the implant in pseudoexfoliative glaucoma. Researchers will compare the results with data from patients with open-angle glaucoma.

Inclusion Criteria:

Data will be collected for all patients with pseudoexfoliation glaucoma (PXFG), ocular hypertension (OHT) and pseudoexfoliation syndrome, POAG and other secondary open angle glaucoma (OAG) diagnosed, who underwent surgery from 2018 to 2022.

Patients should be candidates for filtering glaucoma surgery for the following indications:

• uncontrolled intraocular pressure (IOP)
• intolerance or non-adherence to topical treatment
• glaucoma progression despite topical therapy
• surgical cataract patients undergoing phacoemulsification, who were treated with two or more hypotensive drugs and wished to withdraw the medication due to side effects and/or discomfort of the treatment.

Refractory glaucoma and eyes with previous filtering surgery, previous laser treatments or micropulse transscleral cyclophotocoagulation will be also included.

Exclusion Criteria:

• Patients with follow up less than 12 months.
• Patients with end-stage glaucoma, uveitic and angle closure glaucoma.

Data will be collected for all patients with PXFG, POAG and other secondary OAG, who underwent surgery from 2018 to 2022, at 2 terciary care academic ophthalmology centers (University Hospital Complex of Ferrol and University Hospital Complex of Santiago de Compostela, Spain) by 10 surgeons.